Press Release
Orelabrutinib Data Presented at the 63rd Annual Meeting of ASH
13 Dec, 2021
148
3623
InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List
03 Dec, 2021
143
3616
InnoCare Announces the Clearance of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 by U.S. FDA
15 Nov, 2021
97
3599
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development
12 Nov, 2021
89
3596
InnoCare to Present Orelabrutinib Data at the Upcoming 63rd Annual Meeting of ASH
08 Nov, 2021
113
3590
InnoCare Announces Approval of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China
19 Oct, 2021
112
3579
BIOGEN AND INNOCARE ANNOUNCE DOSING OF FIRST PATIENT IN PHASE 2 CLINICAL TRIAL OF ORELABRUTINIB FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN CHINA
14 Oct, 2021
103
3612
Mantle Cell Lymphoma Clinical Trail Sites in U.S.
01 Oct, 2021
118
3571